Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of pegylated arginine deiminase (ADI-PEG 20) in pediatric patients
who deficient in the expression of tumor argininosuccinate synthetase, and have failed prior
treatments. The study hypothesis is that this drug will be safe in pediatric patients.